立体定向放疗对比全脑放疗治疗EGFR突变非小细胞肺癌脑转移:提前终止的III期HYBRID试验结果与反思
III期HYBRID试验针对EGFR突变非小细胞肺癌脑转移患者,比较立体定向放疗(SRT)与全脑放疗(WBRT)的非劣效性,因入组缓慢提前终止,仅入组85例(WBRT组41例,SRT组44例)。18个月颅内进展率分别为9.5%与10.2%,中位颅内无进展生存期分别为21.4与22.3个月(P均>0.05),SRT组总生存和认知功能保留更优(P均<0.05)。
要点
- 针对EGFR突变非小细胞肺癌脑转移,SRT与WBRT在18个月颅内进展率(9.5% vs 10.2%)及中位颅内无进展生存期(21.4 vs 22.3个月)上无显著差异。
- SRT组总生存和认知功能保留均优于WBRT组(P均<0.05)。
- 试验因入组缓慢提前终止,主要原因是患者不愿承担WBRT导致的神经认知功能下降风险。
核心结论
- 尽管该III期试验把握度不足,但未发现SRT相较于WBRT在EGFR突变非小细胞肺癌脑转移患者中造成结局损害的 evidence。
- 涉及不含认知保护措施的WBRT的随机试验在当前时代可能面临入组不足的高风险。
- 推荐开展分子/生物学分层患者的试验。
研究设计与样本
- III期随机对照试验HYBRID(NCT02882984),纳入初治EGFR突变非小细胞肺癌且脑转移灶≤5个(任何大小)的患者。
- 患者从WBRT(37.5 Gy/15次)或SRT(每个肿瘤体积25-40 Gy/5次)第一天起开始第一代酪氨酸激酶抑制剂治疗。
- 主要终点为18个月颅内无进展生存期(意向性治疗分析),筛查208例后入组85例(WBRT组41例,SRT组44例),中位随访分别为31个月和36个月。
主要发现
- 18个月时颅内进展发生率WBRT组为9.5%,SRT组为10.2%。
- 中位颅内无进展生存期WBRT组为21.4个月,SRT组为22.3个月(P>0.05)。
- SRT组总生存和认知功能保留均优于WBRT组(P均<0.05)。
- 入组率低的最主要原因是患者不愿承担WBRT导致的神经认知功能下降风险。
关键数值与推荐
- WBRT剂量方案为37.5 Gy分15次。
- SRT剂量方案为每个肿瘤体积25-40 Gy分5次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 该III期试验把握度不足(underpowered)。
- 试验因入组缓慢而提前终止,筛查208例后仅入组85例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: All known randomized trials of stereotactic radiotherapy (SRT) versus whole brain radiotherapy (WBRT) for brain metastases (BMs) comprise mixed histologies. The phase III HYBRID trial (NCT02882984) attempted to evaluate the non-inferiority of SRT vs. WBRT specifically for EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) BMs. METHODS: Inclusion criteria were ≤ 5 BMs (any size) from treatment-naïve EGFRm NSCLC. All patients started a first-generation tyrosine kinase inhibitor on the first day of WBRT (37.5 Gy/15 fractions) or SRT (25-40 Gy/5 fractions per tumor volume). The primary endpoint was 18-month intracranial progression-free survival (iPFS; intention-to-treat). RESULTS: The trial commenced in June 2015 and was closed in April 2021 after screening 208 patients but enrolling 85 (n = 41 WBRT, n = 44 SRT; median follow-up 31 and 36 months, respectively). Respectively, 9.5 % vs. 10.2 % of patients experienced intracranial progression at 18 months, and the median iPFS was 21.4 vs. 22.3 months (p > 0.05 for all). The SRT arm experienced higher overall survival and cognitive preservation (p < 0.05 for all). The most notable reason for low enrollment was patients not wishing to risk neurocognitive decline from WBRT. CONCLUSIONS: Although this phase III trial was underpowered, there was no evidence that SRT yielded outcome detriments compared to WBRT for EGFRm NSCLC BMs. Lessons from prematurely closed trials are valuable, as they often provide important experiential perspectives for investigators designing/executing future trials. In the current era, randomized trials involving WBRT without cognitive sparing measures may be at high risk of underaccrual; trial investigators are encouraged to carefully consider our experience when attempting to design such trials. However, trials of molecular-/biologically-stratified patients are highly recommended as the notion of "individualized medicine/oncology" continues to expand.
引用
- Zeng M, Verma V, Chen X, et al. Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial. Radiother Oncol. 2024. PMID: 38801945. doi:10.1016/j.radonc.2024.110334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。